Eisbach Bio is developing EIS-12656, which works by inhibiting ALC1 (chromodomain-helicase-DNA-binding protein 1-like), a chromatin remodeller and DNA helicase also ...

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.

BX-004 is under development for the treatment of cystic fibrosis, non-cystic fibrosis bronchiectasis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation.

S-309309 is under clinical development by Shionogi and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...

SNK-396 is under development for the treatment of elevated low-density lipoprotein cholesterol. It is administered through subcutaneous route and is being developed based on siRNA technology platform.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.

Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.

ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.